Comparative Pharmacology
Head-to-head clinical analysis: ANDROID 25 versus TESTRED.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANDROID 25 versus TESTRED.
ANDROID 25 vs TESTRED
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Android 25 contains methyltestosterone, a synthetic androgen that binds to androgen receptors, promoting protein synthesis and anabolic effects. It also inhibits gonadotropin secretion from the pituitary, reducing endogenous testosterone production.
Testosterone is an androgen receptor agonist, promoting development of male secondary sexual characteristics and anabolic effects.
Testosterone 25 mg subcutaneously or intramuscularly every 2 to 4 weeks. Alternatively, 125 mg intramuscularly every 10 days.
Testosterone enanthate 200 mg intramuscularly every 2 weeks.
None Documented
None Documented
Terminal elimination half-life: 10–100 minutes (testosterone); clinical context: rapid clearance necessitates frequent dosing or use of esters for sustained effect
Terminal elimination half-life for testosterone is 2-4 hours; testosterone enanthate has a half-life of 4-5 days due to slow release from the oily depot. Clinical context: shorter half-life requires more frequent dosing for stable serum levels.
Renal: 90% (as glucuronide and sulfate conjugates, 5–10% unchanged); fecal/biliary: 10%
Approximately 90% of administered testosterone is excreted in urine as glucuronide and sulfate conjugates of testosterone and its metabolites (androsterone, etiocholanolone). About 6% is excreted in feces via bile. Unchanged testosterone excretion is negligible (<1%).
Category C
Category C
Androgen
Androgen